U.S., Aug. 20 -- ClinicalTrials.gov registry received information related to the study (NCT07130916) titled 'A Study of Aumolertinib in European Participants With Non-Small Cell Lung Cancer' on July 31.
Brief Summary: This is a Phase 1, open-label, multicenter, multiple-dose study to evaluate aumolertinib in European participants with a confirmed diagnosis of activating EGFR mutation positive (EGFRm+) locally advanced or metastatic NSCLC.
Study Start Date: Dec. 05, 2024
Study Type: INTERVENTIONAL
Condition:
Non-Small Cell Lung Cancer
Intervention:
DRUG: Aumolertinib
In Part A, participants will receive aumolertinib 110 mg (2 x 55 mg tablet) once daily, orally administrated under fasted condition (fasting from 2 hours before to 1 hou...